Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Axcan launches once-daily Canasa
Axcan received a three-year marketing exclusivity for the new dosage form under the non-patent exclusivity provisions of the Federal Food, Drug and Cosmetic Act. “The once-a-day Canasa 1,000mg
Axcan received a three-year marketing exclusivity for the new dosage form under the non-patent exclusivity provisions of the Federal Food, Drug and Cosmetic Act. “The once-a-day Canasa 1,000mg
This clinical trial is an open-label dose escalation phase I/II study in which a single dose of Reolysin will be administered by infusion to patients with recurrent malignant
The companies are voluntarily suspending supply of Tysabri from commercial distribution and have requested that physicians stop prescribing the treatment. In addition, the companies have suspended dosing in
Under the amended agreement, Abbott will distribute and market Numax, MedImmune’s investigational second-generation anti-RSV (respiratory syncytial virus) monoclonal antibody (MAb) currently in phase III development, upon approval outside
A second agent from this program, OSI-817, is currently being evaluated in preclinical toxicology experiments prior to entry into the clinic. Both these drug candidates are potent tyrosine
In the phase I/II study, PA-457 was administered as a single oral dose to HIV-infected patients who were not on other therapy, in order to determine the pharmacokinetics
The agreements focus on the cell-based validation of collections of candidate genes previously identified by Schering AG as possible therapeutic drug targets. Cenix will apply its industry-leading expertise
The service, called esymbio, aims to create an infrastructure that will foster collaboration between biotechnology companies, investors and public bodies to drive the development of the region’s life
SOT-375, known as Eligard in the US, is an injectable formulation of leuprolide acetate designed to deliver 3.75mg of the drug substance at a controlled rate over 30
This favorable review from Japan’s Ministry of Health, Labour and Welfare (MHLW) follows a committee review meeting and will form the basis on which the Japanese government will